Cargando…
Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland
Cefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR E. coli isolates der...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785875/ https://www.ncbi.nlm.nih.gov/pubmed/36558842 http://dx.doi.org/10.3390/pathogens11121508 |
_version_ | 1784858155453251584 |
---|---|
author | Zalas-Więcek, Patrycja Płachta, Katarzyna Gospodarek-Komkowska, Eugenia |
author_facet | Zalas-Więcek, Patrycja Płachta, Katarzyna Gospodarek-Komkowska, Eugenia |
author_sort | Zalas-Więcek, Patrycja |
collection | PubMed |
description | Cefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR E. coli isolates derived from clinical samples of hospitalized patients. Disk diffusion (DD) and MIC (minimum inhibitory concentration) test strip (MTS) methods were used. The results were interpreted based on EUCAST (version 12.0 2022) recommendations. Among all E. coli isolates, 98 (94.2%) and 99 (95.2%) were susceptible to CFDC when the DD and MTS methods were used, respectively (MIC range: <0.016–4 µg/mL, MIC(50): 0.19 µg/mL, MIC(90): 0.75 µg/mL). With the DD and MTS methods, all (MIC range: 0.016–2 µg/mL, MIC(50): 0.19 µg/mL, MIC(90): 0.75 µg/mL) but three (96.6%) ESBL-positive isolates were susceptible to CFDC. Out of all the metallo-beta-lactamase-positive E. coli isolates (MIC range: 0.016–4 µg/mL, MIC(50): 0.5 µg/mL, MIC(90): 1.5 µg/mL), 16.7% were resistant to CFDC with the DD method, while 11.1% were resistant to CFDC when the MTS method was used. CFDC is a novel therapeutic option against MDR and XDR E. coli isolates and is promising in the treatment of carbapenem-resistant E. coli strains, also for those carrying Verona integron-encoded metallo-beta-lactamases, when new beta-lactam-beta-lactamase inhibitors cannot be used. |
format | Online Article Text |
id | pubmed-9785875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97858752022-12-24 Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland Zalas-Więcek, Patrycja Płachta, Katarzyna Gospodarek-Komkowska, Eugenia Pathogens Article Cefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR E. coli isolates derived from clinical samples of hospitalized patients. Disk diffusion (DD) and MIC (minimum inhibitory concentration) test strip (MTS) methods were used. The results were interpreted based on EUCAST (version 12.0 2022) recommendations. Among all E. coli isolates, 98 (94.2%) and 99 (95.2%) were susceptible to CFDC when the DD and MTS methods were used, respectively (MIC range: <0.016–4 µg/mL, MIC(50): 0.19 µg/mL, MIC(90): 0.75 µg/mL). With the DD and MTS methods, all (MIC range: 0.016–2 µg/mL, MIC(50): 0.19 µg/mL, MIC(90): 0.75 µg/mL) but three (96.6%) ESBL-positive isolates were susceptible to CFDC. Out of all the metallo-beta-lactamase-positive E. coli isolates (MIC range: 0.016–4 µg/mL, MIC(50): 0.5 µg/mL, MIC(90): 1.5 µg/mL), 16.7% were resistant to CFDC with the DD method, while 11.1% were resistant to CFDC when the MTS method was used. CFDC is a novel therapeutic option against MDR and XDR E. coli isolates and is promising in the treatment of carbapenem-resistant E. coli strains, also for those carrying Verona integron-encoded metallo-beta-lactamases, when new beta-lactam-beta-lactamase inhibitors cannot be used. MDPI 2022-12-09 /pmc/articles/PMC9785875/ /pubmed/36558842 http://dx.doi.org/10.3390/pathogens11121508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zalas-Więcek, Patrycja Płachta, Katarzyna Gospodarek-Komkowska, Eugenia Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland |
title | Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland |
title_full | Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland |
title_fullStr | Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland |
title_full_unstemmed | Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland |
title_short | Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland |
title_sort | cefiderocol against multi-drug and extensively drug-resistant escherichia coli: an in vitro study in poland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785875/ https://www.ncbi.nlm.nih.gov/pubmed/36558842 http://dx.doi.org/10.3390/pathogens11121508 |
work_keys_str_mv | AT zalaswiecekpatrycja cefiderocolagainstmultidrugandextensivelydrugresistantescherichiacolianinvitrostudyinpoland AT płachtakatarzyna cefiderocolagainstmultidrugandextensivelydrugresistantescherichiacolianinvitrostudyinpoland AT gospodarekkomkowskaeugenia cefiderocolagainstmultidrugandextensivelydrugresistantescherichiacolianinvitrostudyinpoland |